Zyversa Therapeutics Inc (ZVSA)

11:27 AM

ZyVersa Therapeutics Inc. Stock Analysis and ForecastMarket-beating performance - Autocar Professional

11:27 AM

09:18 AM

What analysts say about ZyVersa Therapeutics Inc. stockExceptional profit potential - Autocar Professional

09:18 AM

Jul 22, 2025

Is ZyVersa Therapeutics Inc. a good long term investmentTremendous gains - jammulinksnews.com

Jul 22, 2025

Jul 22, 2025

What drives ZyVersa Therapeutics Inc. stock priceOutstanding capital growth - jammulinksnews.com

Jul 22, 2025

Jul 21, 2025

ZyVersa Therapeutics CEO Issues Mid-year Shareholder Letter - GlobeNewswire

Jul 21, 2025

Jul 21, 2025

ZyVersa secures $12 million in financing to advance kidney disease trials - Investing.com

Jul 21, 2025

Jul 21, 2025

ZyVersa Therapeutics Updates Shareholders on Key Developments and R&D Milestones in Mid-Year Letter - Nasdaq

Jul 21, 2025

Jul 21, 2025

ZyVersa Therapeutics Raises $12M to Accelerate Breakthrough Kidney and Inflammatory Disease Treatments - Stock Titan

Jul 21, 2025

Jul 17, 2025

ZVSA’s Market Whiplash: -93.65% YTD Decline, -52.27% Plunge in 30 Days - investchronicle.com

Jul 17, 2025

Jul 17, 2025

Why ZyVersa Therapeutics Inc. stock attracts strong analyst attentionFree Best Performing Stock Suggestions - Newser

Jul 17, 2025

Jul 16, 2025

ZyVersa Therapeutics to be delisted from Nasdaq, trading to move to OTC market - Investing.com India

Jul 16, 2025

Jul 16, 2025

ZyVersa Therapeutics Faces Nasdaq Delisting, Plans Pink Market Move - TipRanks

Jul 16, 2025

Jul 16, 2025

ZyVersa Therapeutics to be delisted from Nasdaq, trading to move to OTC market By Investing.com - Investing.com South Africa

Jul 16, 2025

Jul 15, 2025

How ZyVersa Therapeutics Inc. stock performs during market volatilityWatchlist Winner Update - Newser

Jul 15, 2025

Jul 15, 2025

What makes ZyVersa Therapeutics Inc. stock price move sharplyFree Stock Selection with 300% Return - Newser

Jul 15, 2025

Jul 12, 2025

ZyVersa Therapeutics (NASDAQ:ZVSA) Rating Increased to Hold at Wall Street Zen - Defense World

Jul 12, 2025

Jul 11, 2025

ZyVersa Therapeutics (ZVSA) Stock Price, News & Analysis - MarketBeat

Jul 11, 2025

Jul 10, 2025

ZyVersa Therapeutics Supports FDA-Authorized Emergency Compassionate Use of Cholesterol Efflux Mediator?? VAR 200 in A Patient with ApoCII Amyloidosis - MarketScreener

Jul 10, 2025

Jul 10, 2025

Why Did ZyVersa Therapeutics Plunge 10% Despite Funding Boost? - AInvest

Jul 10, 2025

Jul 09, 2025

ZyVersa Therapeutics (NASDAQ:ZVSA) Shares Up 17.4% – Time to Buy? - Defense World

Jul 09, 2025

Jul 08, 2025

ZyVersa Therapeutics Supports FDA-Authorized Emergency - GlobeNewswire

Jul 08, 2025

Jul 08, 2025

ZyVersa Secures $2 Mln Through Warrant Inducement Deal With Institutional Investor - Nasdaq

Jul 08, 2025

Jul 08, 2025

ZVSA’s Stock Journey: What Investors Need to Know About ZyVersa Therapeutics Inc’s Performance - investchronicle.com

Jul 08, 2025

Jul 08, 2025

Why Did ZyVersa Therapeutics Stock Shoot Higher On Tuesday? - Benzinga

Jul 08, 2025

Jul 08, 2025

Intensity Therapeutics Inc’s Shares Reel: -85.34% Quarterly Revenue Decline Amid 7.38M Market Cap - investchronicle.com

Jul 08, 2025

Jul 08, 2025

ZyVersa announces warrant inducement transaction for $2M in gross proceeds - TipRanks

Jul 08, 2025

Jul 08, 2025

ZyVersa Therapeutics Announces a Warrant Inducement Transaction for $2.0 Million in Gross Proceeds - GlobeNewswire

Jul 08, 2025

Jul 08, 2025

Biotech ZyVersa Raises $2M in Strategic Warrant Deal to Advance Drug Development Pipeline - Stock Titan

Jul 08, 2025

Jul 08, 2025

Astria Therapeutics Inc (ATXS) Stock: Uncovering 52-Week Market Trends - investchronicle.com

Jul 08, 2025

Jul 08, 2025

ZyVersa’s VAR 200 approved for emergency use in rare kidney disease - Investing.com

Jul 08, 2025

Jul 08, 2025

ZyVersa Therapeutics Supports FDA-Authorized Emergency Compassionate Use of Cholesterol Efflux Mediator™ VAR 200 in a Patient with ApoCII Amyloidosis - The Manila Times

Jul 08, 2025

Jul 08, 2025

FDA Grants Emergency Access to ZyVersa's VAR 200 Drug for Ultra-Rare Kidney Disease Treatment - Stock Titan

Jul 08, 2025

Jul 08, 2025

ZyVersa’s VAR 200 approved for emergency use in rare kidney disease By Investing.com - Investing.com South Africa

Jul 08, 2025

Jun 26, 2025

ZyVersa Therapeutics (ZVSA) Launches Phase 2a Study for DKD Treatment | ZVSA Stock News - GuruFocus

Jun 26, 2025

Jun 26, 2025

ZyVersa begins patient recruitment for kidney disease drug trial - Investing.com

Jun 26, 2025

Jun 26, 2025

ZyVersa begins patient recruitment for kidney disease drug trial By Investing.com - Investing.com South Africa

Jun 26, 2025

Jun 26, 2025

ZyVersa Therapeutics (ZVSA) Secures Funding Deal to Advance Kidn - GuruFocus

Jun 26, 2025

Jun 25, 2025

ZyVersa enters $10 million share purchase agreement with WVH By Investing.com - Investing.com UK

Jun 25, 2025

Jun 25, 2025

ZyVersa Therapeutics announcs share purchase agreement for up to $10M - TipRanks

Jun 25, 2025

Jun 16, 2025

Critical Analysis: ZyVersa Therapeutics (NASDAQ:ZVSA) vs. Schrödinger (NASDAQ:SDGR) - Defense World

Jun 16, 2025

Jun 14, 2025

ZyVersa Therapeutics (NASDAQ:ZVSA) Upgraded at Wall Street Zen - Defense World

Jun 14, 2025

Jun 12, 2025

ZyVersa Therapeutics Stockholders Approve Key Proposals - TipRanks

Jun 12, 2025

Jun 11, 2025

Reviewing Belite Bio (NASDAQ:BLTE) & ZyVersa Therapeutics (NASDAQ:ZVSA) - Defense World

Jun 11, 2025